guest ::
| Home > Publications Database > Application of IVDr NMR spectroscopy to stratify Parkinson's disease with absolute quantitation of blood serum metabolites and lipoproteins. > print |
| Home > Publications Database > Application of IVDr NMR spectroscopy to stratify Parkinson's disease with absolute quantitation of blood serum metabolites and lipoproteins. > print |
| 001 | 278919 | ||
| 005 | 20250605100737.0 | ||
| 024 | 7 | _ | |a 10.1038/s41598-025-01352-0 |2 doi |
| 024 | 7 | _ | |a pmid:40404791 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12098827 |2 pmc |
| 037 | _ | _ | |a DZNE-2025-00645 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 600 |
| 100 | 1 | _ | |a Berezhnoy, Georgy |b 0 |
| 245 | _ | _ | |a Application of IVDr NMR spectroscopy to stratify Parkinson's disease with absolute quantitation of blood serum metabolites and lipoproteins. |
| 260 | _ | _ | |a [London] |c 2025 |b Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1749040345_5050 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The challenge of early detection and stratification in Parkinson's disease (PD) is urgent due to the current emergence of mechanism-based disease-modifying treatments. In here, metabolomic and lipidomic parameters obtained by a standardized and targeted in vitro diagnostic research (IVDr) platform have a significant potential to address therapy-related questions and generate improved biomarker panels. Our study aimed to use IVDr nuclear magnetic resonance (NMR) spectroscopy to quantify metabolites and lipoproteins in PD blood serum from different cohorts to stratify metabolically driven subtypes of idiopathic and genetic PD. Serum aliquots from three neurodegeneration biobank cohorts (287 samples in total, including 62 PD patient samples with GBA mutation, 98/43 PD patient samples of early/late stages of disease duration, 20 PD samples from patients with mutations in recessive PD genes and some smaller subgroups of mitochondrial and double mutation cases) were prepared and analyzed with IVDr NMR spectroscopy, covering 39 blood serum metabolites and 112 lipoprotein parameters. Uni- and multivariate statistics were used to identify metabolism-driven changes under consideration of typical confounders such as age, sex and disease duration and set into context with clinical biomarkers such as CSF concentrations of alpha-synuclein, neurofilament light chain, and tau protein. Based on the different PD subgroups we performed a total of eight different comparisons. Highlights from these comparisons include increased citrate and dimethylglycine with a decrease of creatinine and methionine in healthy controls and early PD group compared to GBA, PD late and recessive PD. We furthermore identified decreased HDL-3 free cholesterol in genetic PD cases compared to sporadic subject samples (sum of the PD early and PD late groups). Considering medication, we found that the levodopa equivalent daily dose (LEDD) is mostly positively correlated with tyrosine and citrate in sporadic PD compared to pyruvate and phenylalanine in genetic PD. Cerebrospinal fluid levels of alpha-synuclein were negatively correlated with alanine. Further metabolites and lipoproteins with discriminatory power for double mutation PD cases involved ornithine, 2-aminobutyrate and 2-hydroxybutyrate as well as for mitochondrial phenotypes via LDL phospholipid, apolipoprotein and cholesterol subfractions. Quantitative IVDr NMR serum spectroscopy is able to stratify PD patient samples of different etiology and can contribute to a wider understanding of the underlying metabolism-driven alterations e.g. in energy, amino acid, and lipoprotein metabolism. Though our overall cohort was large, major confounders such as age, sex and medication have a strong impact. That is why absolute quantification and detailed patient knowledge about metabolic confounders, is a premise for future translation of NMR serum spectroscopy to routine PD diagnostics. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a GBA |2 Other |
| 650 | _ | 7 | |a Biomarkers |2 Other |
| 650 | _ | 7 | |a Blood |2 Other |
| 650 | _ | 7 | |a Dementia |2 Other |
| 650 | _ | 7 | |a Parkinson’s disease |2 Other |
| 650 | _ | 7 | |a Recessive inheritance |2 Other |
| 650 | _ | 7 | |a Lipoproteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: blood |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Lipoproteins: blood |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Spectroscopy: methods |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Metabolomics: methods |2 MeSH |
| 650 | _ | 2 | |a Mutation |2 MeSH |
| 700 | 1 | _ | |a Bae, Gyuntae |b 1 |
| 700 | 1 | _ | |a Wüst, Leonie |b 2 |
| 700 | 1 | _ | |a Schulte, Claudia |0 P:(DE-2719)9000366 |b 3 |u dzne |
| 700 | 1 | _ | |a Cannet, Claire |b 4 |
| 700 | 1 | _ | |a Wurster, Isabel |0 P:(DE-2719)2812736 |b 5 |u dzne |
| 700 | 1 | _ | |a Zimmermann, Milan |b 6 |
| 700 | 1 | _ | |a Jäck, Alexander |0 P:(DE-2719)9002626 |b 7 |u dzne |
| 700 | 1 | _ | |a Spruth, Eike Jakob |0 P:(DE-2719)2812446 |b 8 |
| 700 | 1 | _ | |a Hellmann-Regen, Julian |0 P:(DE-2719)9003016 |b 9 |u dzne |
| 700 | 1 | _ | |a Roeske, Sandra |0 P:(DE-2719)2810395 |b 10 |u dzne |
| 700 | 1 | _ | |a Pürner, Dominik |b 11 |
| 700 | 1 | _ | |a Glanz, Wenzel |0 P:(DE-2719)2811614 |b 12 |u dzne |
| 700 | 1 | _ | |a Maass, Fabian |0 P:(DE-2719)9001334 |b 13 |
| 700 | 1 | _ | |a Hufschmidt, Felix |0 P:(DE-2719)9002827 |b 14 |u dzne |
| 700 | 1 | _ | |a Kilimann, Ingo |0 P:(DE-2719)2810394 |b 15 |u dzne |
| 700 | 1 | _ | |a Dinter, Elisabeth |0 P:(DE-2719)9001016 |b 16 |u dzne |
| 700 | 1 | _ | |a Kimmich, Okka |0 P:(DE-2719)9002382 |b 17 |u dzne |
| 700 | 1 | _ | |a Gamez, Anna |0 P:(DE-2719)9001536 |b 18 |u dzne |
| 700 | 1 | _ | |a Levin, Johannes |0 P:(DE-2719)2811659 |b 19 |u dzne |
| 700 | 1 | _ | |a Priller, Josef |0 P:(DE-2719)2811122 |b 20 |u dzne |
| 700 | 1 | _ | |a Peters, Oliver |0 P:(DE-2719)2811024 |b 21 |u dzne |
| 700 | 1 | _ | |a Wagner, Michael |0 P:(DE-2719)2000057 |b 22 |u dzne |
| 700 | 1 | _ | |a Storch, Alexander |0 P:(DE-2719)9000306 |b 23 |u dzne |
| 700 | 1 | _ | |a Lingor, Paul |0 P:(DE-2719)2812561 |b 24 |u dzne |
| 700 | 1 | _ | |a Düzel, Emrah |0 P:(DE-2719)2000005 |b 25 |u dzne |
| 700 | 1 | _ | |a van Riesen, Christoph |0 P:(DE-2719)9001486 |b 26 |u dzne |
| 700 | 1 | _ | |a Wüllner, Ullrich |0 P:(DE-2719)2000056 |b 27 |u dzne |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 28 |u dzne |
| 700 | 1 | _ | |a Falkenburger, Björn |0 P:(DE-2719)2814178 |b 29 |u dzne |
| 700 | 1 | _ | |a Bähr, Mathias |0 P:(DE-2719)2811350 |b 30 |u dzne |
| 700 | 1 | _ | |a Zerr, Inga |0 P:(DE-2719)2000058 |b 31 |u dzne |
| 700 | 1 | _ | |a Petzold, Gabor C |0 P:(DE-2719)2810273 |b 32 |u dzne |
| 700 | 1 | _ | |a Spottke, Annika |0 P:(DE-2719)2811324 |b 33 |u dzne |
| 700 | 1 | _ | |a Rizzu, Patricia |b 34 |
| 700 | 1 | _ | |a Brosseron, Frederic |0 P:(DE-2719)2810593 |b 35 |u dzne |
| 700 | 1 | _ | |a Schäfer, Hartmut |b 36 |
| 700 | 1 | _ | |a Gasser, Thomas |0 P:(DE-2719)2320009 |b 37 |u dzne |
| 700 | 1 | _ | |a Trautwein, Christoph |b 38 |
| 773 | _ | _ | |a 10.1038/s41598-025-01352-0 |g Vol. 15, no. 1, p. 17738 |0 PERI:(DE-600)2615211-3 |n 1 |p 17738 |t Scientific reports |v 15 |y 2025 |x 2045-2322 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/278919/files/DZNE-2025-00645%20SUP.zip |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/278919/files/DZNE-2025-00645.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/278919/files/DZNE-2025-00645.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:278919 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9000366 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2812736 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)9002626 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2812446 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)9003016 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2810395 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2811614 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)9002827 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2810394 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)9001016 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 17 |6 P:(DE-2719)9002382 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)9001536 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 19 |6 P:(DE-2719)2811659 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 20 |6 P:(DE-2719)2811122 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2811024 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 22 |6 P:(DE-2719)2000057 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 23 |6 P:(DE-2719)9000306 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 24 |6 P:(DE-2719)2812561 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)2000005 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 26 |6 P:(DE-2719)9001486 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 27 |6 P:(DE-2719)2000056 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 28 |6 P:(DE-2719)2000026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 29 |6 P:(DE-2719)2814178 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 30 |6 P:(DE-2719)2811350 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 31 |6 P:(DE-2719)2000058 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 32 |6 P:(DE-2719)2810273 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 33 |6 P:(DE-2719)2811324 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 35 |6 P:(DE-2719)2810593 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 37 |6 P:(DE-2719)2320009 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SCI REP-UK : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-07-29T15:28:26Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-07-29T15:28:26Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-18 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1011201 |k AG Wagner |l Neuropsychology |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)5000006 |k AG Düzel |l Clinical Neurophysiology and Memory |x 4 |
| 920 | 1 | _ | |0 I:(DE-2719)1011103 |k AG Spottke |l Clinical Research Platform (CRP) |x 5 |
| 920 | 1 | _ | |0 I:(DE-2719)1011401 |k Clinical Research Platform (CRP) |l Clinical Research Platform (CRP) |x 6 |
| 920 | 1 | _ | |0 I:(DE-2719)1510100 |k AG Teipel |l Clinical Dementia Research (Rostock /Greifswald) |x 7 |
| 920 | 1 | _ | |0 I:(DE-2719)1710012 |k AG Falkenburger |l Translational Parkinson Research |x 8 |
| 920 | 1 | _ | |0 I:(DE-2719)1011001 |k Clinical Research (Bonn) |l Clinical Research Coordination |x 9 |
| 920 | 1 | _ | |0 I:(DE-2719)5000007 |k AG Priller |l Translational Neuropsychiatry |x 10 |
| 920 | 1 | _ | |0 I:(DE-2719)5000000 |k AG Peters |l Biomarker-Assisted Early Detection of Dementias |x 11 |
| 920 | 1 | _ | |0 I:(DE-2719)5000014 |k AG Storch |l Non-Motor Symptoms in Parkinson's disease |x 12 |
| 920 | 1 | _ | |0 I:(DE-2719)1410002 |k AG Fischer |l Epigenetics and Systems Medicine in Neurodegenerative Diseases |x 13 |
| 920 | 1 | _ | |0 I:(DE-2719)1011302 |k AG Wüllner |l Biomarker Parkinson's Disease |x 14 |
| 920 | 1 | _ | |0 I:(DE-2719)1440015 |k Clinical Dementia Research (Göttingen) |l Clinical Dementia Research (Göttingen) |x 15 |
| 920 | 1 | _ | |0 I:(DE-2719)1440011-1 |k AG Zerr |l Translational Studies and Biomarker |x 16 |
| 920 | 1 | _ | |0 I:(DE-2719)1013020 |k AG Petzold |l Vascular Neurology |x 17 |
| 920 | 1 | _ | |0 I:(DE-2719)1011303 |k AG Heneka |l Neuroinflammation, Biomarker |x 18 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | _ | _ | |a I:(DE-2719)1011201 |
| 980 | _ | _ | |a I:(DE-2719)5000006 |
| 980 | _ | _ | |a I:(DE-2719)1011103 |
| 980 | _ | _ | |a I:(DE-2719)1011401 |
| 980 | _ | _ | |a I:(DE-2719)1510100 |
| 980 | _ | _ | |a I:(DE-2719)1710012 |
| 980 | _ | _ | |a I:(DE-2719)1011001 |
| 980 | _ | _ | |a I:(DE-2719)5000007 |
| 980 | _ | _ | |a I:(DE-2719)5000000 |
| 980 | _ | _ | |a I:(DE-2719)5000014 |
| 980 | _ | _ | |a I:(DE-2719)1410002 |
| 980 | _ | _ | |a I:(DE-2719)1011302 |
| 980 | _ | _ | |a I:(DE-2719)1440015 |
| 980 | _ | _ | |a I:(DE-2719)1440011-1 |
| 980 | _ | _ | |a I:(DE-2719)1013020 |
| 980 | _ | _ | |a I:(DE-2719)1011303 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|